On Demand Pharmaceuticals Announces Preferred Supplier Relationship with Azzur Group

Published on : Published by : BioBuzz Media

On Demand Pharmaceuticals Announces Preferred Supplier Relationship with Azzur Group
NEWS PROVIDED BY
On Demand Pharmaceuticals
Jun 01, 2022, 12:00 ET
SHARE THIS ARTICLE
Building Off Success of Commissioned cGMP Facility
ROCKVILLE, Md., June 1, 2022 /PRNewswire/ — On Demand Pharmaceuticals, Inc. (ODP), an innovative technology company transforming the way medicines are made, announced today that it has signed a Preferred Supplier agreement with Azzur Group through 2024. The transformation of ODP’s Rockville Headquarters into a State-of-the-Art cGMP Medicine Manufacturing facility began with Azzur in the fall of 2020.
Azzur collaborated in designing ODP’s GMP Roadmap and helped develop the strategy and execution plan for ushering in this latest addition to Maryland’s Biotech Hub. Building on the strategy, Azzur worked alongside ODP to initiate a Managed Services approach to execution, providing a single source for Commissioning services, Equipment rentals, Technology subscriptions, and a series of outsourced packages covering Environmental Monitoring, Training, and Documentation.
Dr. John Lewin, ODP’s Chief Medical Officer, said “The flexibility Azzur demonstrated to accommodate the fluid nature of a startup and the challenges we all faced during the COVID-19 pandemic was remarkable. Having the ability to pull on a variety of resources and expertise, when we needed…

On Demand Pharmaceuticals Commissions State-of-the-Art, cGMP Medicine Manufacturing Facility

Published on : Published by : BioBuzz Media

On Demand Pharmaceuticals Commissions State-of-the-Art, cGMP Medicine Manufacturing Facility The facility represents a critical first step in a new era of drug manufacturing aimed at strengthening domestic supply chain resiliency [….]

On Demand Pharmaceuticals Among the top 10 Emerging Technologies of 2021

Published on : Published by : BioBuzz Media

Making pharmaceuticals on demand
Medicines today are generally made in large batches, in a multi-step process with different parts dispersed in locations around the world. It can take months to complete the process, involving hundreds of tons of material, which creates some challenges in consistency and reliable supply. Advances in microfluidics and on-demand drug manufacturing now enable a small but increasing number of common pharmaceuticals to be made as needed.
Also called continuous-flow manufacture, the process moves ingredients via tubes into small reaction chambers. The drugs can be made in portable machines in remote locations or field hospitals, with doses tailored to individual patients, a remaining challenge is reducing the high cost of this emerging technology.